1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Phase 2 Maximum Tolerated Dose determined in Phase 1: new trials by email Literature Review of Phase 2 Maximum Tolerated Dose determined in Phase 1 trials Research Report on Phase 2 Maximum Tolerated Dose determined in Phase 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3 - Leukemia, High Risk Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 100 | 2025-03-21 | 2026-04-15 |
Anemia, Refractory, with Excess of Blasts (1) · Bone Marrow Failure Disorders (1) · Congenital Bone Marrow Failure Syndromes (1) · Hemoglobinopathies (1) · Immunologic Deficiency Syndromes (1) · Leukemia (1) · Lymphoma, Non-Hodgkin (1) · Metabolism, Inborn Errors (1)
Children's Hospital of Philadelphia (1)
United States (1)